← Stock Trading Canary · All insider profiles
INSIDER PROFILE · SE
Magnus Erreth
Annan medlem i bolagets administrations-, lednings- eller kontrollorgan
Profile key: se|magnus erreth
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 1
- Purchases · 24M
- 2
- Average purchase
- SEK 62,750
- Gross purchase value
- SEK 125,500
- Last purchase
- 2025-12-30
- Completed 20D events
- 2.0
- Outcome status
- INSUFFICIENT_SAMPLE
Latest company: EQL Pharma AB
Companies: EQL Pharma AB
Post-purchase outcomes
Benchmark-relative outcomes are available against OMX Stockholm 30.
- Excess return = stock return − OMX Stockholm 30 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small sample | 100.0% (2/2) | 0.0% (0/2) | -8.3% | -8.3% | -9.2% |
| 20D | 2Small sample | 100.0% (2/2) | 0.0% (0/2) | -9.5% | -9.5% | -18.4% |
| 60D | 2Small sample | 100.0% (2/2) | 0.0% (0/2) | -23.9% | -23.9% | -36.4% |
| 120D | 2Small sample | 100.0% (2/2) | 0.0% (0/2) | -51.4% | -51.4% | -68.6% |
Research patterns
- First purchase in 12M
- 1/2
- Large purchase ≥ €100k
- 0/2
- Cluster buying · 15D
- 1/2
- Buying the dip · ≥20% below prior 52W high
- 2/2
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.